Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading XCUR daily closes…
Loading price history…
Pipeline assets
GPC-100
Phase 2 · ActiveModality: small molecule
Target chemokine receptor
Partnerships GPCR Therapeutics Inc: License and Collaboration Agreement (Jan 2025) to develop/commercialize GPCR technologies; milestones on clinical trials, marketing authorizations, net sales + recurring royalties ($1M milestone payable Q2 2026, to be satisfied in common stock due to limited cash).
Indications
Stem cell mobilization in multiple myeloma patients(Phase 2)
Status note Small molecule chemokine-receptor antagonist. Phase 2 in blood cancer patients eligible for HSCT completed Jan 2026; current trial combines GPC-100 with propranolol for stem cell mobilization in multiple myeloma. Company otherwise evaluating strategic alternatives.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.